Table 2.

Level of agreement with statements about extending the cervical cancer screening interval to 3 years after a normal co-test^a, according to screening interval recommendations, among 82 providers at Federally Qualified Health Centers, Illinois, 2009–2010.

			Recommend 1-year interval (%) (n = 57)	Recommend 3-year interval (%) (n = 25)	p-Value
Extending the screening interval would…	Result in patient not visiting annually for other screening tests (reverse)	Agree	75	80	0.555
Neither	7	12
Disagree	18	8
Put patient at increased risk for cervical cancer	Agree	40	12	0.036
Neither	23	32
Disagree	37	56
Result in higher rates of cervical pre-cancer	Agree	35	20	0.055
Neither	23	12
Disagree	42	68
Cause patients to lose contact with medical care system	Agree	68	48	0.088
Neither	9	24
Disagree	23	28
Do the following entities encourage or discourage you to extend the screening interval?	Patients	Discourage	18	40	0.105
Neither	67	48
Encourage	16	12
Colleagues	Discourage	28	16	0.165
Neither	47	40
Encourage	25	44
Clinic administration	Discourage	21	20	0.126
Neither	65	56
Encourage	14	24
Professional journals	Discourage	16	0	0.000
Neither	36	20
Encourage	47	80
Professional specialty organizations	Discourage	20	0	0.000
Neither	36	20
Encourage	45	80
National health organizations	Discourage	16	0	0.051
Neither	31	24
Encourage	53	76

Significance of associations between these two interval recommendations and beliefs was tested with ordered logistic regression and adjusted for clustered sampling design. No missing data.

^aCo-test (simultaneous Pap and human papillomavirus test).